Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 41 clinical trials
Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)

This study aims to compare the efficacy and safety of reduced adjuvant XELOX treatment (4 cycles of XELOX followed by 4 cycles of capecitabine alone) to standard adjuvant XELOX treatment (8

adenocarcinoma
immunostimulants
xelox regimen
oxaliplatin
capecitabine
  • 0 views
  • 17 Mar, 2022
  • 1 location
Neoadjuvant Chemoradiotherapy vs. Chemotherapy With Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer

three cycles of XELOX therapy or neoadjuvant chemotherapy alone using XELOX regimen following D2 gastrectomy and adjuvant chemotherapy for 3 cycles. The primary end point is disease free survival (DFS

immunostimulants
cancer chemotherapy
xelox regimen
capecitabine
oxaliplatin
  • 6 views
  • 22 Jan, 2021
  • 1 location
Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

This is a randomized, open-label phase III study. The treatment was compare the efficacy and safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus capecitabine (XELOX) treating

tegafur
platelet count
cancer chemotherapy
xelox regimen
neutrophil count
  • 0 views
  • 01 Mar, 2022
  • 1 location
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

This is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure

adenocarcinoma
oxaliplatin
folfox regimen
capecitabine
xelox
  • 0 views
  • 04 Oct, 2022
  • 1 location
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) plus standard first-line combination chemotherapy regimens for selected gastrointestinal (GI) cancers. Eligible patients include those with unresectable, locally advanced, recurrent or metastatic HER2-expressing gastroesophageal adenocarcinoma (GEA), biliary tract …

  • 4 views
  • 29 May, 2022
  • 20 locations
Perioperative FLOT vs Adjuvant XELOX for CA Stomach

This is a single centre randomised controlled trial, comparing perioperative FLOT versus adjuvant XELOX for locally advanced gastric and esophagogastric junction cancers. Patients with operable

  • 0 views
  • 13 Apr, 2022
  • 1 location
Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal Metastasis

IPXELOX will investigate the safety, tolerability, and antitumor activity of intraperitoneal paclitaxel in combination with chemotherapy in patients with advanced gastric cancer with peritoneal metastasis. Study hypotheses: Intraperitoneal paclitaxel administered to subjects at the recommended phase 2 dose will show manageable safety and tolerability and anti-tumor efficacy with systemic capecitabine …

oxaliplatin
xelox regimen
cancer chemotherapy
capecitabine
neutrophil count
  • 0 views
  • 12 Jul, 2021
  • 1 location
ibi308 Combined With Bevacizumab + XELOX Regimen in Advanced Colorectal Cancer

a phase II clinical study of IBI308 combined with bevacizumab + XELOX regimen in the treatment of patients with metastatic colorectal cancer. a total of 8 courses of medication would be given. A

  • 0 views
  • 09 Jan, 2022
  • 1 location
Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients

This prospective, single arm study aims to evaluate the preoperative neoadjuvant safety of Sintilimab combined with XELOX plus bevacizumab in colorectal patients with liver metastasis and pMMR

  • 0 views
  • 02 Jul, 2021
  • 1 location
Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC

This is a two-group, parallel, randomized, standard-control phase II study comparing the safety and efficacy of trifluridine/tipiracil combined with oxaliplatin and bevacizumab versus XELOX plus

  • 0 views
  • 03 Nov, 2021
  • 1 location